CF
VIR icon

CNA Financial’s Vir Biotechnology VIR Stock Holding History

CNA Financial’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,192
Closed -$197K – 161
2022
Q3 		$197K Sell
10,192
-3,500
-26% -$89K 0.07% 162
2022
Q2 		$349K Sell
13,692
-1,850
-12% -$43.2K 0.12% 152
2022
Q1 		$400K Buy
15,542
+1,790
+13% +$53.1K 0.12% 160
2021
Q4 		$576K Buy
13,752
+1,760
+15% +$69K 0.15% 149
2021
Q3 		$522K Buy
11,992
+50
+0.4% +$2.17K 0.14% 156
2021
Q2 		$565K Buy
11,942
+1,070
+10% +$48.6K 0.16% 153
2021
Q1 		$557K Sell
10,872
-6,880
-39% -$371K 0.17% 152
2020
Q4 		$475K Buy
17,752
+5,520
+45% +$179K 0.15% 164
2020
Q3 		$420K Buy
12,232
+1,300
+12% +$56K 0.15% 147
2020
Q2 		$448K Buy
+10,932
New +$367K 0.18% 133

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CNA Financial's VIR Position: Q4 2022 in Review

CNA Financial sold out of Vir Biotechnology (VIR) in Q4 2022, closing a stake of 10,192 shares — an estimated $197K sold.

CNA Financial first reported a position in VIR in Q2 2020 and held it in 10 quarters. The position peaked at $576K in Q4 2021. 223 funds tracked by Wall St. Rank hold VIR as of Q4 2022.

  • CNA Financial reported no remaining Vir Biotechnology position as of Q4 2022 after selling out during the quarter.
  • CNA Financial sold 10,192 Vir Biotechnology shares in Q4 2022, an estimated $197K.
  • CNA Financial first reported a position in Vir Biotechnology in Q2 2020 and held it in 10 quarters.
  • CNA Financial's Vir Biotechnology position peaked at $576K in Q4 2021.
  • 223 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2022.

Based on CNA Financial's 13F filing for Q4 2022, filed 10 Feb 2023.